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Abstract
Background: Reaching the 90–90-90 targets requires efficient resource use to deliver HIV testing and treatment
services. We investigated the costs and efficiency of HIV services in relation to HIV testing yield in rural Karonga
District, Malawi.
Methods: Costs of HIV services were measured over 12months to September 2017 in five health facilities, drawing on
recognised health costing principles. Financial and economic costs were collected in Malawi Kwacha and United States
Dollars (US$). Costs were calculated using a provider perspective to estimate average annual costs (2017 US$) per HIV
testing episode, per HIV-positive case diagnosed, and per patient-year on antiretroviral therapy (ART), by facility. Costs
were assessed in relation to scale of operation and facility-level annual HIV positivity rate. A one-way sensitivity analysis
was undertaken to understand how staffing levels and the HIV positivity rate affected HIV testing costs.
Results: HIV testing episodes per day and per full-time equivalent HIV health worker averaged 3.3 (range 2.0 to 5.7).
The HIV positivity rate averaged 2.4% (range 1.9 to 3.7%). The average cost per testing episode was US$2.85 (range
US$1.95 to US$8.55), and the average cost per HIV diagnosis was US$116.35 (range US$77.42 to US$234.11), with the
highest costs found in facilities with the lowest daily number of tests and lowest HIV yield respectively. The mean
facility-level cost per patient-year on ART was approximately US$100 (range US$90.67 to US$115.42). ART drugs were
the largest cost component averaging 71% (range 55 to 76%). The cost per patient-year of viral load tests averaged
US$4.50 (range US$0.52 to US$7.00) with cost variation reflecting differences in the tests to ART patient ratio across
facilities.
Conclusion: Greater efficiencies in HIV service delivery are possible in Karonga through increasing daily testing episodes
among existing health workers or allocating health workers to tasks in addition to testing. Costs per diagnosis will increase as
yields decline, and therefore, encouraging targeted testing strategies that increase yield will be more efficient. Given the
contribution of drug costs to per patient-year treatment costs, it is critical to preserve the life-span of first-line ART regimens,
underlining the need for continuing adherence support and regular viral load monitoring.
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Background
Renewed global efforts are being made to bring the HIV
epidemic under control, notably through the release of
the UNAIDS 90–90-90 targets in 2014 [1], and the sub-
sequent World Health Organization (WHO) recommen-
dations for universal “Test and Start” for HIV in 2015
[2]. As a result, the number of people on antiretroviral
therapy (ART) in eastern and southern Africa reached
11.7 million in 2016, representing 60% of all people liv-
ing with HIV (PLHIV) in the region [3].
At the individual level, the benefits of timely initiation
of ART among those who test HIV positive include im-
proved life expectancy and lower risks of opportunistic
infections [4]. At the population level, the benefits of
achieving the 90–90-90 targets would include reduced
HIV transmission, including of drug-resistant HIV
strains, in turn reducing the social and economic burden
of HIV [5, 6]. Despite the urgency of achieving these
health and development advantages, global financing for
HIV has levelled since the global economic crisis of
2008–09 [7]. Innovations in HIV financing and increased
domestic funds are being sought both nationally and
internationally [8–10]. It has also been argued that more
efficient use of existing resources, through regular re-
source allocation assessments, would make an essential
contribution to addressing the funding gap [3, 11].
To understand the affordability of HIV services re-
quires an assessment of its costs which is critical to esti-
mating budgetary requirements. At the same time, these
data contribute to the understanding of how to improve
planning and allocate existing resources to maximise
value for money or efficiency. While large scale, multi-
site cost data are generally required to capture the vari-
ability in costs and efficiency [12], information on HIV
service costs in sub-Saharan Africa are limited [13].
Moreover, few analyses exist of how costs might change
as the epidemic and corresponding care and treatment
strategies evolve.
In Malawi, the HIV epidemic remains generalised with
an estimated adult HIV prevalence of 10.6% by 2016
[14]. Seventy-three percent of PLHIV in Malawi self-
report knowing their HIV status (67% among men and
77% among women), 89% of whom are on ART of which
91% are virally suppressed [14]. These achievements in
testing and treatment coverage reflect progress in the
national scale-up of HIV testing services and HIV care
and treatment, a process which accelerated in 2011 with
the introduction of Option B+, lifelong HIV treatment
for all pregnant women living with HIV, and subsequent
adoption of Treat-all policies in 2016 [15].
While these achievements are impressive, new strat-
egies, including better targeting of HIV testing and care
and treatment, will be needed to achieve the 90–90-90
targets in Malawi. However, further expansion of
targeting HIV services is dependent on resource avail-
ability. Assessing the resource requirements and there-
fore, affordability, requires an understanding of the costs
of service delivery, data which can also help to ensure
better and more efficient use of existing resources and
to improve planning and budgeting. To date, cost studies
in Malawi have exclusively examined either the costs of
HIV testing or the costs of ART, or have estimated costs
at a time when previous HIV policy guidelines were im-
plemented (Table s1) [16–18]. As such, research is
needed that provides facility-based costs of HIV testing
and care and treatment services in the context of univer-
sal test and treat, particularly in rural areas which typify
the context of most HIV treatment programmes. In this
context, the aim of this study was to assess how facility
characteristics and HIV testing positivity rate impacts on
costs and efficiency of HIV services in a rural district in
northern Malawi.
Methods
Facility-based HIV services in Malawi
In 2016, the Ministry of Health (MoH) in Malawi re-
leased updated guidelines on HIV testing and on the
clinical management of HIV in adults and children in
efforts to move closer to its goal of achieving universal
access to ART [19, 20]. The MoH, supported by imple-
menting partners, works with its regional and district
health offices to provide HIV prevention and treatment
services in accordance with these guidelines (Table s2).
These services are supported by a number of national
and district-level activities including surveillance and
auditing visits, quality assurance of services, and moni-
toring and evaluation (M&E) activities which involves
the routine collection, recording, analysis, and reporting
of Health Management Information Systems (HMIS)
data. The HMIS is a national database of records on key
health indicators, including on HIV, for each facility.
Study setting
Malawi is divided into three regions (Central; Northern
and Southern Regions) which are further sub-divided
into a total of 28 districts. Karonga District, Northern
Region, was selected for this study because it hosts a
health and demographic surveillance site (HDSS) in the
southern part of the District. The HDSS continuously
monitors demographic events among a population of ap-
proximately 40,000 residents through annual surveil-
lance rounds [21]. Since 2013, bi-annual health facility
surveys have been conducted in all facilities (n = 5) pro-
viding HIV services to the HDSS population in order to
assess HIV service delivery [22], although the HDSS
does not offer any service support to these facilities. The
third round additionally included a nested costing study.
In 2015–16, HIV prevalence among adults (ages 15–49
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years) was estimated at 8.7% (in males) and 10.5% (in fe-
males) in Karonga District [23].
Facility characteristics
All five HDSS health facilities were included in this
study. Three facilities are classified as clinics (one small
and two large) and two facilities are classified as a hos-
pital (one small and one medium size) (Table 1). Two
clinics (Clinics A and C) have a delivery ward. Three fa-
cilities are government-run (public) and two facilities are
faith-based.
Cost study
The methodology for this cost study drew on costing
guidelines for HIV prevention strategies and on the prin-
ciples of the “Reference case for global health costing,
2017”, a guide developed to assist researchers in the
process of generating transparent and comparable cost
estimates [24, 25].
This study was undertaken from the health providers’
perspective (governments and donors), and estimates the
cost of core facility-based HIV testing and treatment ser-
vices. Costs include those associated with activities
which occur within each facility, and those that are man-
aged at the district and the national level and which are
essential to the delivery of the service (Table s2).
HIV testing services, defined as facility-based testing
using rapid HIV tests, includes the provision of both
pre- and post-test counselling, first test and confirma-
tory testing, and training of health care workers on HIV
testing. HIV treatment services include the provision of
antiretroviral medicines according to the 2016 national
guidelines, Cotrimoxazole preventive therapy, viral load
laboratory tests, patient monitoring, and the training of
health workers on care and treatment. There are five
standard first-line ART regimens, of which two fixed-
dose combinations (one adult and one paediatric) are
used for ART initiation, and three standard second-line
ART regimens (Table s3) [20]. Isoniazid preventive ther-
apy is not included because Karonga District is not clas-
sified as a high-risk tuberculosis area [19]. Within the
treatment protocol patients make regular visits to clinics
to collect ART drugs and for other treatments, counsel-
ling and viral load testing [20].
Data collection
A standardised Microsoft Excel-based instrument was
used to record resource use and, where available, price
information from each facility. Data were collected
retrospectively for the 12months to September 2017.
Most data collection took place during October and No-
vember 2017. Resources were categorised into capital in-
puts (buildings/room space, equipment, and staff
training) and recurrent inputs (personnel, HIV test kits,
ART, Cotrimoxazole, viral load tests, other clinical and
non-clinical supplies, overheads, and national/district
supervision, auditing, and M&E visits).
Service delivery data were captured from two sources
1) HMIS; and 2) from facility records (registers, sum-
mary reports, and ART patient cards). Routine data on
persons tested for HIV were extracted from facility reg-
isters. Data extracted from ART patient cards were ART
regimen and number of tablets by month of visit. In fa-
cility E, patient utilisation data were obtained from
monthly summaries compiled by clinical staff.
Cost approach
Two types of costs were estimated: 1) financial costs, de-
fined as the actual expenditure incurred on resource in-
puts (salaries, HIV test kits, ART, Cotrimoxazole and
other HIV supplies), and 2) economic costs, defined as
the value of all resource inputs, including donated or
subsidised items, which were valued at their market
price (rent, capital equipment and volunteer time). A
micro-costing approach, a method which identifies and
values each input consumed in delivering a service [25],
was applied which used a combination of top-down and
bottom-up approaches to obtain resource use and costs
depending on the line item.
Capital inputs: Physical space and office equipment
used to deliver HIV services was audited and measured
during visits to each facility. Shared usage across testing
and treatment services was identified from interviews
with staff. The cost of space used was estimated from
rental costs for equivalent nearby spaces. Prices for
Table 1 Facility characteristics [source facility survey; HMIS]
Facility Size/typea Authority Number outpatient attendanceb Location
Clinic A Small clinic Faith-based 3437 Remote rural
Clinic B Large clinic Public 25,451 Rural
Clinic C Large clinic Public 17,778 Remote rural
Hospital D Small hospital Faith-based 5464 Rural
Hospital E Medium hospital Public 36,535 Rural
aFacility type classified by facility in-charge. Size classified by authors and is based on number of outpatient visits i.e. small clinic & small hospital < 10,000
outpatient visits per annum
bAnnual outpatient attendance from October 2016 to September 2017
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office equipment (e.g. furniture and medical equipment)
were obtained from the Karonga District Health Office
and from medical suppliers in the country. Capital
equipment prices were annualised over 25 years. Train-
ing costs, provided to health workers in the previous 2
years, were estimated using information provided by the
District Health Office, (staff per diems and travel ex-
penses) and by national non-governmental organisations
running HIV training programs (unit “per participant”
training costs). Staff training costs were annualised over
2 years, in line with MoH guidelines that all registered/
certified HIV service providers are to receive training at
2 year intervals [19, 20].
Recurrent inputs: Staff delivering HIV services were
interviewed to illicit the amount of time that workers
spent on different HIV services and salaries were appor-
tioned accordingly. Salaries (wages and benefits) were
collected from either the facilities (two faith-based facil-
ities) or from the District Health Office. Per diems for
lay counsellors were collected from the staff.
Prices of HIV test kits and other clinical and non-
clinical supplies (including national HIV testing registers
and HIV patient treatment cards) were obtained from
medical suppliers based in Lilongwe. Drug costs (ART
and Cotrimoxazole) were obtained from The Global
Fund ART pricing list for 2017 [26]. Laboratory costs of
viral load tests were obtained from organisations provid-
ing the service, and the cost of reagents etc. from med-
ical supplies organisations. Overhead costs included the
cost of utilities (electricity, water, buildings and equip-
ment maintenance, telecoms, waste water, and adminis-
tration in Clinic B and both hospitals, and electricity,
water and telecoms in Clinics A and C). Overheads costs
were apportioned to the HIV service based on the size
of space used to deliver the service. Facility audits,
supervision and M&E cost information (salaries, allow-
ances, accommodation, transport expenses, and airtime)
were provided by the MoH and by the Karonga District
Health Office.
Cost analysis
Facility survey data were analysed using STATA v15.
Facility-level cost and outcome calculations were under-
taken using Microsoft Excel 2007. Total annual costs
and average (unit) costs were calculated for each facility
and separately for HIV testing and for HIV care and
treatment services. All costs were adjusted to 2017
United States dollars (US$) using an average exchange
rate over the 12month study timeframe (1 US$ = 724.35
Malawi Kwacha) [27]. Because all costs were collected in
current prices, adjustment for inflation was not required.
The levels of technical efficiency (relationship between
inputs to the service outputs) and economic efficiency
(relationship between the monetary value of the inputs
to the service outputs) of HIV testing and HIV care and
treatment were estimated as:
1) HIV testing services: The cost per testing episode
(full testing procedure for an individual and which
may include confirmatory testing) and per HIV case
detected were calculated by dividing the total
facility costs of running testing services in 1 year by
the number of testing episodes, and the number of
new HIV-positive individuals identified over the
same timeframe (annual HIV positivity rate).
2) HIV care and treatment: The annual cost per
patient-year for ART care was calculated by divid-
ing the total annual costs of providing care and
treatment services by the number of HIV patients
receiving care and treatment.
A one-way sensitivity analysis, varying one parameter
at a time holding all others constant, was undertaken to
understand how staffing levels and the annual HIV posi-
tivity rate affected the costs of HIV testing services. Cost
variations were explored by applying a +/− 10% variation
range to staffing levels and the annual positivity rate,
and by applying annual HIV positivity rates observed in
studies from other settings in Malawi.
Results
HIV testing service delivery and costs
The mean number of health workers who provided HIV
testing services across the five facilities was 7.4 (range 3 to
13) yielding an average of 3.3 full time equivalent (FTE)
per facility (total 16.3 FTE; range 1 to 4.6 FTE), of which
approximately 3.0 (total 15.1; range 0.6 to 4.0 FTE) were
counsellors (professional and lay) (Tables 2 & s4).
A total of 12 health workers were trained in HIV test-
ing in the past 2 years (nine from Clinic B, three from
Clinic A). No health workers were trained in HIV testing
during these 2 years at the other facilities. HIV testing
surveillance or audits were conducted on a quarterly
basis in all five facilities, and supervision visits were con-
ducted every month.
Over the 12months to September 2017, a total of 18,509
HIV testing episodes (1st tests, 2nd tests and confirmatory)
were conducted. The mean number of testing episodes per
facility was 3702 (range 520 to 9544). The average number
of new HIV positive cases across all five facilities was 91
(total 453; range 19 to 240), yielding an average annual HIV
positivity rate of 2.4% (range 1.9 to 3.7%).
Based on the number of days per week that facilities
conducted HIV tests (7 days Hospital E, 6 days Hospital
D, and 5 days in the three clinics), the number of HIV
testing episodes conducted per day and per FTE HIV
testing staff averaged 3.3 (range 2.0 Clinic A to 5.7 Hos-
pital E). No clear trend was observed over the 12-month
Vyas et al. BMC Health Services Research          (2020) 20:740 Page 4 of 11
period in the number of HIV tests undertaken by month
and per facility (Fig. 1). In facilities B and E, testing ac-
tivity peaked in February and June respectively.
The total annual cost of HIV testing in the facilities
ranged from $4448 (Clinic A) to $18,582 (Hospital E)
(Table 3). The cost per testing episode averaged $2.85
(range $1.95 Hospital E to $8.55 Clinic A). There was
also variation in the cost per new HIV positive case de-
tected across the facilities which averaged $116.35 (range
$77.42 Hospital E to $234.11 Clinic A). There was an in-
verse relationship between the number of testing epi-
sodes and the cost per testing episode, however, no clear
trend was observed between the cost per person diag-
nosed and facility annual HIV-positive yield.
Recurrent costs, in particular personnel followed by
the cost of test kits, comprised the majority of total HIV
testing costs (Fig. 2). Health worker time represented
50.0% of all HIV testing costs (range 40.6% Hospital E to
62.3% Clinic C). HIV test kits accounted for 31.4% of all
testing costs (range 10.3% Clinic A to 45.9% Hospital E).
National and district-level service delivery costs (supervi-
sion, audits and M&E), accounted for 7.1% of HIV test-
ing costs (range 4.0% Hospital E to 16.8% Clinic A).
Sensitivity analysis
When staff inputs were varied by +/− 10%, the mean
cost per person diagnosed with HIV changed by +/− 5%
and ranged from $110.49 to $122.20 (Table 4). Varying
the annual positivity rate by +/− 10% resulted in a +/−
11% change in the mean cost per person diagnosed;
range $105.77 to $129.28. Applying an annual positivity
rate of 9%, as observed elsewhere in Malawi, reduced the
mean cost per person diagnosed by 73% to $31.64.
When stratified by facility type, authority and location,
higher mean costs per HIV case identified were observed
in clinics versus hospitals (Fig. 3a), faith-based facilities
versus public facilities (Fig. 3b), and remote rural versus
rural facilities (Fig. 3c). The cost per person diagnosed
was highest in remote rural facilities (US$215.49), and
lowest in hospitals (US$93.57). The annual HIV positiv-
ity rate, however, varied very little across the strata
(Table s5)
HIV treatment service delivery and costs
The mean number of health workers who provided ART
services was 8.4 per facility (total 42; range 2 to 17), and
the mean number of FTE per facility was 2.5 (total
12.7 FTE; range 0.4 to 4.5 FTE) (Tables 5 & s4). Sixty-
nine percent (29 of 42 of health workers who provided
care and treatment had received ART training in the
previous 2 years. All health workers providing care and
treatment in each of the three clinics and in Hospital D
had been trained in ART, compared with 23.5% (4 of 17)
health workers who were trained in Hospital E. In all
five facilities, national-level supervision visits for care
and treatment services were reportedly conducted every
quarter and district-level auditing was undertaken every
month.
The number of ART current patients totalled 2110
across the five facilities (range 187 to 1021). The total
number of newly initiated ART patients over the 12
months was 412 (range 13 to 223), which equates to
91% of the new HIV-positive cases (n = 453) identified
over the timeframe. The total number of viral load tests
was 678 (range 7 to 362).
The proportion of patients on paediatric ART aver-
aged 5.6% (range 3.6 to 6.8%), and all were on the first-
line 3TC/AZT/NVP regimen. Among the 1992 adult
ART patients, 92.4% were on the first-line regimen
TDF/3TC/EFV 300/300/600, with a further 5.6% on a
different first-line regimen. Only 2% of adult ART pa-
tients were on second-line regimens. On average, ART
was dispensed to patients every 2.9 months or 4.1 times
per patient-year (range every 2.6 to 3.2 months, or 3.8 to
4.7 times per patient-year).
The total annual HIV care and treatment costs
ranged from $19,003 (Clinic A) to slightly over $100,
000 (Hospital E) (Table 6). The mean facility-level
Table 2 Number of HIV tests conducted from October 2016 to September 2017




New positive Annual positivity rate
Clinic A 4 / 3 1.0 0.6 520 26 19 3.7%
Clinic B 9 / 9 4.0 4.0 3144 178 74 2.4%
Clinic C 3 / 0 2.5 2.5 1916 64 36 1.9%
Hospital D 13 / 0 4.2 4.0 3385 152 84 2.5%
Hospital E 8 / 0 4.6 4.0 9544 553 240 2.5%
Total 37 / 12 16.3 15.1 18,509 973 453
Average 7.4 / 2.4 3.3 3.0 3702 195 91 2.4%
aIncludes lay (volunteer) counsellors: 2 in Clinic C
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care and treatment cost per patient-year was almost
$100 ($99.35); range $90.67 (Clinic C) to $115.42
(Hospital D).
Recurrent costs contributed the most to total costs,
of which ART drugs were the largest cost component
averaging 71% across the five facilities (range 55%
Hospital D to 76% Hospital E). This translated to an
average ART drug cost of $70.73 US per patient-year
across the five facilities (range $63.89 to $75.04).
Cotrimoxazole drug costs contributed, on average, a
Fig. 1 Number of HIV testing episodes by health facility and by month
Table 3 Annual HIV testing services costs; cost per testing episode (cost per test); and cost per HIV case diagnosed (cost per HIV) in
2017 US$ (October 2016 to September 2017)










































Building 115 0.22 6.04 14 0.00 0.19 22 0.01 0.60 26 0.01 0.30 215 0.02 0.90
Equipment 15 0.03 0.80 78 0.02 1.05 13 0.01 0.36 65 0.02 0.77 33 0.00 0.14
Training 393 0.76 20.69 1179 0.38 15.94 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00
Total capital 523 1.01 27.53 1272 0.40 17.19 35 0.02 0.96 90 0.03 1.08 249 0.03 1.04
RECURRENT COSTS
Personnel 2109 4.06 111.02 5116 1.63 69.13 4615 2.41 128.21 7154 2.11 85.17 7537 0.79 31.40
HIV test kits 458 0.88 24.08 2800 0.89 37.84 1821 0.95 50.59 2954 0.87 35.17 8531 0.89 35.55
Other supplies 179 0.34 9.43 525 0.17 7.09 152 0.08 4.22 635 0.19 7.56 842 0.09 3.51
Utilities & other 433 0.83 22.82 81 0.03 1.09 35 0.02 0.98 155 0.05 1.84 678 0.07 2.82
Total recurrent 3180 6.11 167.35 8521 2.71 115.15 6624 3.46 183.99 10,898 3.22 129.74 17,587 1.84 73.28
DISTRICT/NATIONALCOSTS
Supervision 410 0.79 21.55 410 0.13 5.53 410 0.21 11.38 410 0.12 4.88 410 0.04 1.71
M&E 336 0.65 17.69 336 0.11 4.54 336 0.18 9.33 336 0.10 4.00 336 0.04 1.40
Total District/National 746 1.43 39.24 746 0.24 10.07 746 0.39 20.71 746 0.22 8.88 746 0.08 3.11
TOTAL/ AVERAGE 4448 8.55 234.11 10,538 3.35 142.41 7404 3.86 205.66 11,734 3.47 139.69 18,582 1.95 77.42
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further 6% to total costs, or $5.89 per patient-year.
Personnel comprised the second largest cost compo-
nent (after drugs) averaging 11% (range 4 to 18%) or
$10.79 (range $4.55 to $21.07).
The variability in the average annual per patient cost
of viral load laboratory tests, which ranged from $0.52
(Clinic A) to $7.00 (Hospital D), reflected the differences
across the facilities in the ratio of viral load test per ART
patient over the 12 months which ranged from a low of
4% (Clinic A) to 50% (Hospital D).
Per patient-year costs of capital inputs averaged $4.06
(4% of total costs) across the facilities; range $1.31 (Hos-
pital E) to $13.74 (Hospital D) driven by the cost of
ART training. National and district supervision costs av-
eraged $1.77 per patient-year or 2% of total HIV care
and treatment costs.
Discussion
This district-level case study, to cost the delivery of
facility-based HIV services in the context of Treat-All,
highlights potential areas for cost-saving and has
implications for future resource allocation in terms of
how these services are delivered in this setting. These
findings are particularly timely, given the current flat-
lining of external funding and the imminent approach of
the deadline for the 90–90-90 targets, and indicate key
areas for strategy reform in HIV testing.
HMIS data reveal that the average annual HIV positiv-
ity rate has been declining year on year from 4.4%
(2014) to 2.0% (2018) in these five facilities, suggesting
that identifying new HIV cases through existing facility-
based approaches may be close to reaching saturation.
Our estimate of the mean cost per HIV case diagnosed
(which ranged from US$77.42 to US$234.11) is higher
than documented elsewhere in Malawi, and is likely
driven by the comparatively lower HIV prevalence found
in the area [15, 16]. Our estimate of the mean cost per
testing episode (which ranged from US$1.95 to US$8.55)
is comparable to cost estimates from southern and cen-
tral Malawi and from Zambia, implying that the cost per
HIV case diagnosed is driven by the HIV positivity rate
[16, 17].
Fig. 2 HIV testing resource input share of total HIV testing costs, and average cost per testing episode in US$. ($ figure overlaid in shaded bars is
average cost per testing episode for resource input category)
Table 4 Sensitivity analysis results and percent change in cost in HIV positive person diagnosed
Parameter Range from base estimate 2017 US$ % Change in cost
Staff level (−10% to + 10%) 110.49 122.20 +/− 5%
Annual positivity rate (−10% to + 10%) 129.28 105.77 +/− 11%
Annual positivity ratea 9% 31.64 − 73%
aAs observed elsewhere in Malawi by Mwenge et al. [16]
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While facility-based testing has been a mainstay of
Malawi’s achievement in diagnosing 73% of PLHIV by
2016, our findings suggest refocusing resources to differ-
entiated HIV testing services to identify PLHIV who do
not know their status. This would increase the diagnosis
rate and reduce the cost per diagnosis. Alternative test-
ing strategies such as home- and community-based test-
ing, HIV self-testing, and index tracing are likely to
become more necessary for diagnosing first-time testers
and the hardest-to-reach persons including men and key
populations [28, 29].
Our findings also confirm that as the facility-based
HIV positivity rate declines and the cost per HIV diag-
nosis rises, staff time becomes an increasingly important
contributor to costs. With the number of HIV testing
episodes per FTE health worker per day well below the
national guideline of a maximum of 15 per day, our re-
sults support policies to phase out the use of dedicated
HIV counsellors in facilities, and to move towards
greater role diversity among existing health workers pro-
viding other HIV or general health services. This recom-
mendation, however, should take into account the
numbers and levels of different health workers within a
facility.
We estimated the average per patient-year cost of core
HIV treatment services to be within a relatively narrow
range across the facilities (US$90.67 to US$115.42), sup-
porting the existing centralisation policies of ART
Fig. 3 HIV testing resource input share of total HIV testing costs, and average cost per HIV case detected in $US in a Clinics versus hospital. b Public
versus faith-based facilities. c Remote rural versus rural. ($ figure overlaid in shaded bars is average cost per HIV case diagnosed for resource
input category)
Table 5 HIV care and treatment service delivery (October 2016 to September 2017)
Facility No. ART staff / trained No. FTE ART staff No. ART patients No. ART adult/paediatric No. viral load tests No. initiated in past 12 months
Clinic A 3 / 3 0.4 187 178/9 7 13
Clinic B 10 / 10 4.5 477 459/18 133 83
Clinic C 2 / 2 1.0 233 218/15 80 40
Hospital D 10 / 10 2.4 192 185/7 96 53
Hospital E 17 / 4 4.4 1021 952/69 362 223
Total 42 / 29 12.7 2110 1992 / 118 678 412
Average 8.4 / 5.8 2.5 422 398 / 24 136 82
Vyas et al. BMC Health Services Research          (2020) 20:740 Page 8 of 11
delivery in small rural clinics. Seventy-one percent of an-
nual treatment costs was ART drugs, which is similar to
findings elsewhere in Malawi and in other sub-Saharan
African countries [18]. Preserving the life-span of
cheaper first-line ART drugs becomes increasingly im-
portant as moving to more expensive second-line drugs
will cause the overall annual care and treatment cost to
rise. This underlines the need for better coverage with
viral load monitoring to identify treatment failure, ad-
herence challenges, and to have a sufficient mechanism
in place for prescribing second line treatment. However,
our study findings indicate that current viral load testing
coverage in these facilities does not meet national guide-
lines, which states that viral load testing should be done
at 6 months and 2 years after initiation and then every 2
years thereafter [20]. Although increasing the number of
viral load tests, in line with guidelines, will increase the
cost of care, this gap between guidelines and the actual
implementation of testing needs attention.
Limitations to this study include not costing some
supporting HIV service components, including
community-based testing, early infant diagnosis, or
facility-based index testing. However, use of these testing
mechanisms was very low during the study period. With
respect to HIV treatment, we did not include the
management and treatment of HIV-related illnesses,
prevention services (such as the provision of insecticide-
treated nets; family planning; or post-exposure prophy-
laxis) or home visits for patients who miss appointments.
Further, we did not include patient costs which may act
as a barrier to care. These components should be con-
sidered in future cost studies to ensure more holistic es-
timates of HIV service delivery costs. A second
limitation, as found elsewhere [30], was that record-
keeping across the facilities varied, which meant that
some input prices, typically overheads, had to be esti-
mated if data were not documented by the facility.
Thirdly, our study provides an indication of how costs
might vary across facilities in rural areas, but because of
the small sample size we were unable to confirm these
statistically.
Nevertheless, this study provides detailed cost esti-
mates following standard methodologies that add to the
evidence base around HIV testing and treatment. It also
identified patterns of resource use related to the differ-
ent services, indicating a re-thinking of resource alloca-
tion at the facility level maybe required to improve
efficiency and reduce the unit cost of HIV testing. The
sampled facilities are typical of rural health facilities in
Malawi and the prices of important contributors to cost
Table 6 Annual HIV care and treatment costs; and cost per patient-year on ART in 2017 US$ (October 2016 to September 2017)






















Building 555 2.97 16 0.03 23 0.10 5 0.03 239 0.23
Equipment 17 0.09 129 0.27 52 0.22 13 0.07 53 0.05
Training 786 4.20 2621 5.49 524 2.25 2621 13.65 1048 1.03
Total Capital 1358 7.26 2621 5.49 599 2.57 2639 13.74 1341 1.31
RECURRENT COSTS
Personnel 850 4.55 6668 13.98 1785 7.66 4046 21.07 9411 9.22
ART 12,610 67.43 32,270 67.65 15,482 66.45 12,266 63.89 76,619 75.04
Cotrimoxazole 1098 5.87 2710 5.68 1324 5.68 1061 5.53 6241 6.11
Viral load 98 0.52 1862 3.90 1120 4.81 1344 7.00 5068 4.96
Other supplies 24 0.13 64 0.13 31.34 0.13 27 0.14 142 0.14













Supervision 410 2.19 410 0.86 410 1.76 410 2.13 410 0.40
M&E 336 1.80 336 0.70 336 1.44 336 1.75 336 0.33
Total District/
National
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are set at the national level, suggesting our estimates are
a good basis for making cost estimates elsewhere in the
country. Finally, this study was completed before the
Covid 19 pandemic which may have implications for
achieving the UNAIDS targets.
Conclusion
Moving towards differentiated testing strategies in this
setting can lead to efficiency improvements and there-
fore, freeing up resources for achieving the 90–90-90
goals. Among the recommendations is the increased
sharing of personnel across activities at facilities. This
study also highlights the importance of preserving the
life-span of first-line regimens and therefore, underlines
the need for higher coverage of regular viral load moni-
toring. The results show that these types of cost analysis
continue to be a useful tool in identifying areas for
informing planning, achieving efficiency and freeing up
resources in an era of stagnating funds.
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